Company Update: CVS Caremark Corporation (NYSE:CVS) – CVS Health To Present At The 34th Annual J.P. Morgan Healthcare Conference

[PR Newswire] – WOONSOCKET, R.I., Jan. 4, 2016 /PRNewswire/ — CVS Health Corporation (CVS) today announced that Larry Merlo, the company’s president and chief executive officer, will be making a presentation to investors at the 34th Annual J.P. Morgan Healthcare Conference on January 12, 2016. An audio and video webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website for all interested parties, and will be archived and available for a one-year period. CVS Health is a pharmacy innovation company helping people on their path to better health. Through our more than 9,500 retail pharmacies, more than 1,100 walk-in medical clinics, a leading pharmacy benefits manager with more than 70 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, and expanding specialty pharmacy services, CVS Health enables people, businesses and communities to manage health in more affordable, effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com. Read more on this. CVS Health Corporation (CVS) , valued at $106.76B, opened at $96.04. During today’s session, CVS traded between $95.36 to $96.57 and has traded between $81.37 and $113.65 over the past 12 months. Priced at 18.91x this year’s forecasted earnings, CVS shares are relatively expensive compared to the industry’s 11.03x forward p/e ratio. And for those looking to make a return holding the stock, the company pays shareholders $1.70 per share annually in dividends, yielding 1.71%. According to a consensus of 21 analysts, the earnings estimate of $1.52 per share would be $0.31 better than the year-ago quarter and a $0.02 sequential increase. The full-year EPS estimate is $5.17, which would be a $0.66 better than last year. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $40.97 Billion. If realized, that would be a 10.55% increase over the year-ago quarter. Recently, Goldman downgraded CVS from Buy to Neutral (Dec 17, 2015). Previously, Oppenheimer Initiated CVS at to Outperform. The average price target for CVS shares by the analysts covering the stock is $115.82, which is 20.60% above where the stock opened this morning. See more in (NYSE:CVS) Similar Articles: Market Update (NYSE:MCK): McKesson Corporation to Present at the 34th Annual J.P. Morgan Healthcare Conference Market Update: CVS Caremark Corporation (NYSE:CVS) – CVS Health Corporation Commences Exchange Offers and Consent Solicitations Company Update: CVS Caremark Corporation (NYSE:CVS) – CVS Health Announces New Clinical Affiliations with St. Luke’s University Health Network and TriHealth